USA flag logo/image

An Official Website of the United States Government

IMPROVED HYPOGLYCEMIA RESCUE DEVICE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93736
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK085809
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
XERIS PHARMACEUTICALS, INC.
3208 Red River Street Suite 300 Austin, TX 78705-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: IMPROVED HYPOGLYCEMIA RESCUE DEVICE
Agency: HHS
Contract: 1R43DK085809-01
Award Amount: $157,478.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective of this program is to develop of a clinical prototype, semi-solid drug formulation and auto-injector pen that deliver microliter volumes of a glucagon dose without reconstitution for hypoglycemic emergenci es. To assess the feasibility of this objective, it is necessary to first demonstrate that glucagon can be formulated into an ultra- concentrated, semi-solid formulation and second, that glucagon in a semi-solid formulation is bioavailable and bioactive fo llowing subcutaneous delivery. If successful, these experiments will lead to development of a simple, portable, glucagon delivery system for use in a Phase 1/2 safety-pharmacokinetics study. The first Specific Aim of this proposed project is to develop a p rototype formulation of human glucagon that meets defined criteria for functionality in the delivery device, dissolution in an in vitro model of interstitial fluid and demonstration of short-term, accelerated stability of the glucagon formulation. The seco nd Specific Aim is the successful in vivo delivery of formulations in clinically relevant doses in a rat model. Formulations will be judged by 1) gt80% dissolution of glucagon in simulated interstitial fluid and 2) lt10% residual drug in the device after a dministration. In addition, one (1) months of chemical and physical stability (gt95% API content and equivalent viscosity to day 0) of the solid glucagon formulation will be deemed successful. Effective subcutaneous delivery of glucagon will be assessed by measurement of the drug in the blood using radioimmunoassay. Bioavailability of gt80% relative to a control subcutaneous injection of aqueous-reconstituted glucagon in a rat model will be deemed successful. Meeting these criteria will justify further deve lopment of this novel glucagon delivery system. PUBLIC HEALTH RELEVANCE: The current standard of care for hypoglycemic emergencies-- the glucagon Emergency Kit requires a diabetic's caregiver to reconstitute the peptide powder contained in a vial us ing a 1 mL prefilled syringe and to assure complete solubilization prior to injection. A patient friendly, ready-to-use auto-injector Glucagon Pen will reduce caregiver and patient fear and risk, costs of 911 calls and emergency room visits.

Principal Investigator:

John Kinzell

Business Contact:

Tina Huth
THUTH@RNDBS.COM
Small Business Information at Submission:

XERIS PHARMACEUTICALS, INC.
XERIS PHARMACEUTICALS, INC. 1029 LEA DR, STE B SAN RAFAEL, CA 94903

EIN/Tax ID: 120335242
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No